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Neurofibromatosis 2 (NF2) is an autosomal dominant 
disorder characterized by the occurrence of bilateral 
acoustic neuromas, as well as meningiomas and 
schwannomas. The gene locus for NF2 resides on 
chromosome 22q12 and has been cloned recently. 
Neurilemmomatosis is characterized by multiple cu-
taneous and spinal neurilemmomas without other 
signs of NFl or NF2. Many cases with this disorder 
include the diagnosis of neurofibromatosis or other 
rare diseases unexplained by current nosology. In this 
study, we analyzed the peripheral leukocytes and 
tissue from cutaneous neurilemmomas of seven pa-
T he term neurofibromatosis (NF) has been used to describe two clini cally and gene tically distinct heri-ta ble disorders. NFl , whose gene was cloned in 1990 [1 - 3] , is charac terized by tumors of the periph.eral nervous system, cafe au lait spo ts , and Lisch nodules. 
T he gene locus fo r NFl resides on chromosome 17 q 11. 2 [4] . The 
N Fl gene product (neurofibromin) to a large degree shares a 
common sequence homology with the yeast IRA! and IRA2 
proteins and with the mammal ian ras guanosine triphosphatase 
activator protein, p1 20 GAP [5-7]. T he second type ofneurofibro-
matosis, NF2, is characterized by the occurrence of bilate ral 
acoustic neuromas as we IJ as m eningiomas, ependymomas, and 
schwalU1 om as. In contrast to NFl, cafe au lait spots and neurofi-
bromas are rare, and Lisch nodules are absent; however, posterior 
subcapsul ar cataracts occur in half of patients with NF2 . The gene 
respo nsibl e fo r NF2 ha s been mapped to chromosome 22q12 [8] 
and cloned recentl y [9 ,10]. 
N euriJ emmomatosis, first reported by Niimura in 1973 [11], is 
characterized by multiple pe ripheral (cutaneollS neurilemmomas) 
and spinal schwannomas, without acoustic tumors or the other signs 
of N Fl o r N F2. In neuril emmomas, the tumor consists ofSchwann 
cells. 
In this study, w e an alyzed the peripheral leukocytes and tumors 
from seven patients with neuril emmomatosis using DNA markers 
fo r diffe rent regions of chromosom e 22 . We amplified the NFl and 
N F2 genes and subjected th e polymerase chain reaction (PCR) 
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tients with neurilemmomatosis using DNA markers 
for different regions of chromosome 22. We detected 
allelic losses in three of seven tumors from seven 
patients with a probe for the NF2 region of the long 
arm of chromosome 22 and the germ-line mutations 
in two of three tumors from the same three patients. 
Mutations in the NF2 gene were a deletion from at 
least codon 334 to 579 and G insertion at codon 42 . 
We conclude that the neurilemmomatosis locus lies 
within the NF2 region and that these diseases might 
be identical. Key IVord: gene loclls. ] It west Dertllatol 
104:74-77, 1995 
product to single-strand conformation polymorphism '(SSCP) anal-
ysis . 
MATERIALS AND METHODS 
Patients and Samplcs Seven cutaneous tumor samples from seven 
patients were studied . Thc clinica l information regarding these patients is 
given in Table I. Six of the patients were male and one was female . None 
of the patients had a rnmiJy history. neurologic disorders, or posterior 
subcapsular cataracts. The tissue samples were obtained at surge ry. Histo-
logic diagnoses were made on hcmatoxyl in/ eosin-stained, formalin-fixed, 
paraffin-embedded sections of each tumor. The remaining portion of the 
tumor was frozen immediately in liquid nitrogen and stored at - BO°C until 
isolation of the DNA. Thc tumor contained greater than 70% tumor cells. 
Normal DNA was obtained from leukocytes isolated with 5"!', dextran. 
DNA Extraction Frozen tissue samplcs were ground to a very fine 
powder in liquid nitrogcn. The powder and leukocytes were digested in 50 
mM Tris HCI (PH 7.5) , 150 mM NaCI , 50 mM ethylenediamine tetraacctic 
acid (EDTA), 1% sodium dodecylsulf.1te , and 1 mg/ml proteinase K at 37°C 
overnight. The Iysates were extracted with phenol:chloroform: isoamyl 
alcohol (25:24:1) and precipitated with ethanol. The DNA pellet was dried 
and was resuspendcd in 10 mM Tris HCI (PH 7.5) and 1 mM EDTA (pH 
8.0). 
Probes The fo llowing DNA markers on chromosome 22 were used: 
D22S9 , D22S1, cEW (Ewing Sarcoma breakpoint) . L1F (Icukemia inhibi-
tory fa ctor), D22S15 , D22S32, and MJ3 (myoglobin locus). The probes for 
D22S1 and D22S32 were supplied by the Japanese Cancer Research 
R csources Bank. The probe fo r D22S15 was kindly provided by Dr. Kurnit, 
and the others were supplied by Dr. Nakamura (Cancer Institute, Tokyo, 
Japan). 
Southern Hybridization Five micrograms. of DNA from blood and 
tumor pairs was digested with the appropriate restriction enzyme, electro-
phorescd on 1.0% agarose gels, and transferred to nylon membranes (Pall 
Biodyne transfer membrane) , which were hybridized with plasmid DNA 
probes labeled with [a - 32P]dCTP by random primer extension [12]. To 
eliminate the background of repetitive sequences, we added 125 f.Lg of 
human placental DNA to the hybridization solution (7% polyethylenc 
0022-202X/95/S09.50 • SSDJ0022-202X(94)00251-2 • C opyright © 1995 by The Society for Investigative Dermatology, Inc. 
74 
VOL. 104. NO. 1 JANUARY 1995 
Table I. Clinical Characteristics of Patients With 
Cutaneous Neurilemmomatosis" 
Patient Sex Age T umor Locations 
1 M 42 Skin, sp inal (C4, C6) 
2 M 40 Skin, spinal (C2), Cranial (V) 
3 M 50 Skin, spinal (Th3-4) 
4 F 40 Skin, spinal (Ll-2) 
5 M 59 Skin, spinal (Th9-10, L2) 
6 M 57 Skin, spinal (C3, T h1 2), cranial 
(V , VII , X, II) 
7 M 38 Skin, spinal (C4-6) 
I I N Ollc of the patients had it f.11nily history. 
glycol 8000, 10% sodium dodecylsul f.1te). [n addition, before adding 
membrancs, wc preincubatcd [J2 P]_labcled probc DNA (2 X 10" cpm/ ml) 
in hybridization so lu tion at 65 °C for 1 h. T he membrane was hybridized for 
approximately 12 h at 65°C, washed once in 2 X sodium citratc/sodium 
chloride buffcr for 15 min at room temperature and twice for 15 min at 65°C 
in 0.1 X sodium citrate/sod ium chIoride buffcr and 0.1 % sodium dodecyl-
sul fate, and thcn cxposed to x-ray film for 12-48 h at - 70°C. The 
membranes were stripped in 004 N NaOH and hybridized repeatcdly. 
Allele Loss Allclic loss was infe rred w hen the intcnsity of onc aUele in the 
tumor tissuc was less than 50% of the othcr allele compared to the intensity 
of the two alleles in the corresponding normal sample , as measured by 
densitometry. Loss of heterozygosity was distinguished from chromosome 
duplication by normalizing the signal for the chromosome-22 probc to those 
obtained when the same blots werc rehybridized with probes for loci on 
other ChrOITI OSO lnes, as a contro l of chrOlll0S0nuli content. 
PCR Amplification Oligonucleotide primer pairs of the NFl gene and 
thc NF2 gene used for the PC R-SSCP analysis havc been dcscribed by 
Cawthon ci nl [2] and Rouleau cl nl [10] (Table IT). DNA samples wcre 
amplified using PCR (l min at 94°C. 2 min at 55°C, alld 3 mill at 72°C, 30 
times). Twcnty-microliter PC R rcactions (100 ng of DNA , 1.25 mM of 
each dNTP, 50 mM KCI, 1.25 mM MgCI2. 10 mM T ris pH 804, 0.5 U Taq 
polymerase, 004 p.l of3000 C i [a-J2 PjdCTP/ mmol) with mineral oil were 
run OJ] a PCR 9600 machinc (Perkin Elmer Cetus). 
SSCP Analysis PC R products were diluted 10- fo ld using a buffcr 
consisting of 20 mM EDTA, 0.05% bromophcnol blue, and 0.05%, ",ylenc 
cyanol, and then heated at 95°C for 5 min to dcnaturc the DNA. Samples 
werc applied to ;1 j 0% ncutral polyacrylamide gel (4 9:1 ratio of acrylamidc 
to methylene-bis-acrylamide) containing 0.1 M Tris-borate, 2 mM EDTA. 
by the addition of 5'X. glycerol to the ge l so lution. Elcctrophoresis was 
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carri ed out at 30 W (1300 V, 18 mAl at room temperature, with a fan 
blowing in front of the gel. After electrophoresis. the gels wcre dricd O J] 
vacuum slab dryc rs and were cxposcd ovcrnight with Kodak X-Omat AR 
fi lm . 
DNA Scqucncing Normal D NA from a paticnt who showed allelic loss 
in the tumor was amplified by PCR using the same primers. The PCR 
products were purificd by a Ccntri con 30 column (Amicon) and amplified 
using 3.2 pmol of upstream or downstream primcr. T hc product was 
sequenced dircctly using the dideoxy chain termination method witl, Taq 
polymerase on thc Applied Biosystems DNA sequenccr (Applied BioSys-
tems). 
R ESULTS 
W e detected a loss of heterozygosity for th e DNA m arker 
(D22S15) in o ne of seven tumor samples (Fig lA). The larger 
allelic restriction fragments (3.1 kbp) seen in the BanII digest were 
lost in a tumor from case 2. 
In an additional tumor, an intensity comparison of the bands 
using a densitometer indicated a he mizygous d eletion of the 
sequen ces a t D22S15 (Fig lB). T he h ybridization signals corre-
sponding to the dele ted allele were estimated to be diminished by 
50'Yo . T hereforc, aUe lic losses were shown o n the long arm s of 
chromosom e 22 at D22S15 in two of seven tumo rs. 
Ara i cf al [13] reported one NF2 patient who was discovered to 
have chromosome translocations t(4;·22)(q12;q12.2). T hey tho ught 
that this translocation was disruptin g th e NF2 gene and thus causing 
the disease. Fluorescent ill silll h ybridizatio n and pulsed-field gel 
analyses reveale d that the breakpoint lay between the LIF locus and 
the DNA marker D22S1. T he phys ical distance from the LIF locus 
to D22S1 is 2 cM . They obtained approximately 1 m egabase of 
yeast artifi cial chro moso m e clones around the LIF locus involving 
the NF2 t(4;22) translocation breakpo int region. 
T he LIF pro be detected allelic losses in two of seven tumors, 
from cases 2 and 7. Using an e5 probe, o n the e ndpoint of a yeast 
artificia l chro mosom e clone, the signal from the tumors was 
redu ced dramatically in cases 1, 2, and 7 (Fig lC). However, a 
proximal cosmid clone (Ewing SaTcoma breakpoints, cEW) to e5 
reveale d no sig nificant d e letions of DNA in the tumors. Data are 
summarized in Fig 2 . 
SSCP analysis of the NFl gen e of seven patients showed a normal 
patte rn of SSCP bands. No gross alte rations wcre seen in th e PCR 
product ofNF2 gen e amplified from gen o mic DNA; h owever , on e 
tumor sample (case 2) did n ot amplifY using set- 4 . set- 5, and set- 6 
Table II. Sequences of Primers Used for PCR-SSCP Analyses 
Prinlcr Exons/Codons 
Gene Pair Flanked Sequence 
NFl A 4 5' -A T AA TTGTTGA TGTGA TTTTCA TTG-3 ' 
5' -AA TTTTGAACCAGATGAAGAG-3 ' 
B 5 5'-ATCTAGTATTTTTGAGGCCTCAG-3 ' 
5'-CAGATATGCTATAGTACAGAAGG-3 ' 
C 6 5' -CATATCTGTTTTATCATCAGGAGG-3 ' 
5' -AAGTAAAA TGGAGAAAGGAA CTGG-3' 
7 5' -CAAAA TGAAA A TGGAACTIT AGA-3 ' 
5'-TAAGCATTAAGTACAAATAGCACA-3' 
E 7-9 5 ' -TTTATGTTTGTGCTCTAACACCAAGT-3 , 
5'-ATAAATGCTAGAATGATITCTCATGCT-3 ' 
NF2 39-80 5' -TTGCTCACAGTGTCCTTCCC-3' 
5 ' -TCAGCCCCACCAGTTTCATC-3 ' 
2 150- 172 5'-ATCTTTAGAATCTAATCGC-3' 
5'-AGCTTTCTTTTAGACCACAT-3' 
3 226 - 270 5' -GATCTGCTGGACCCATCTGC-3' 
5' -GA TCTGCTGGACCCA TCTGC-3' 
4 334-374 5' -TCGAGCCCTGTGA TTCAATG-3' 
5' -AAGTCCCCAAGT AGCCTCCT -3 ' 
5 376 - 446 5' -CCCACTTCAGCTAAGAGCAC-3' 
5' -CTCCTCGCCAGTCTGGTG-3 ' 
6 527-579 5' -TCTCACTGTCTGCCCAAG-3' 
5'-GATCAGCAAAATACAAGAAA-3' 
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Figure 1. Autoradiograms from Southern blot analyses of DNAs 
from representative paired tissues demonstrate allelic losses in 
DNAs from tumor (T) and leukocytes (W) in patients with 
neurilemmomatosis . Hybridization was performed with the probes indi-
ca ted (lop) . DNA samples were digested by Banll (A,B) and Pst J (C) . kb, 
kilobases. A) Only one of n.ine cutaneous neurilemmomas- case 
2-showed a loss of heterozygosity for D22S15. B) Jntensity comparison of 
the band indica ted I;emizygous deletion of 022S15 in case 7. C) Decrease 
in NF2 gene (e5) copy number in cases 1 and 2. 
primers. Complete deletion from at least codon 334 to 579 was 
detected in the tumor of case 2 (case 3 in Fig 3). 
Figure 4 shows the results from direc t sequencing of PCR 
product amplifi ed from the set 1 ofNF2 gen e in normal DNA from 
case i. Direct sequencing revealed a G insertion at codon 42, which 
caused a frame shift. 
DISCUSSION 
Bilateral acoustic neuromas· (central n eurofibromatosis), described 
in 1822 by Wishart [14] , were classified as neurofibromatosis 2 
(NF2) in 1988 by the N ation al Institutes of Health Consensus 
D evelopment Conference [15] . NF2 is an autosomal dominant 
disorder with an inc idence of about one in 50,000. The number of 
patie nts with NF2 is es timated to b e about 7000, and every year 150 
n e w patients are born in Japan . During the last 25 years, 1242 
patients with NFl and 48 patients with NF2 were examllled and 
treated he re atJikei University and Tokyo Unive rsity. The patients 
with NF2 developed multiple tumors of the nervous system, 
including nerilemmomas and m eningiomas. The studies for loss of 
h e te rozygosity in both tumors have suggested that the loci of these 
genes are located on the long arm of chromosom e 22. In acoustic 
n e uromas, seven of21 tumors (33%) showed loss of he terozygosity 
ofloci o n human chromosome 22 [16] . These n e urilemmomas and 
probe 
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D22S 1 
EW 
LIF 
D22S I5 
1)22S32 
MB 
All elic losses on the long ar", of chromosollle 22 
2 3 4 6 7 
,-----., 
-
, 
t..J ~ 
-§c-1 ~~ LE.l lJ 
Loss of heterozygosity 
Allelic loss 
Uninformative 
Retained 
Figure 2. Allelic losses by Southern blot analyses on the long arm 
of chromosome 22 in cutaneous neurilemtnomas. EW, Ewing Sar-
coma brcakpoiJlts; LlF, leukemia inhibitory facto'r; ME, myoglobin locus. 
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Figure 3. PCR-SSCP analysis oftbe NF2 gene. The radiolabeled PCI\ 
products were separated by electrophoresis on a 10'X, neutral polyacrylatnid~ 
gel. DNA from tumor in case 3 did not amplity by PCR using set-4 primers 
Complete deletion was detected in the tumor of case 3 (case 2 in Figs 1, 2) : 
meningiomas, such as retinoblastoma or Wilms' tumor, are thought 
to result from the loss or inactivation of a gene, which is classified 
as a recessive tumor suppressor gene. R ecently, the NF2 gene has 
been cloned and sequenced [9 ,10]. The cDNA encodes a 587_ 
amino acid protein with a striking similarity to the proteins moesin, 
ezrin, and radixm. The proteins named m erlin or schwannomin are 
thou ght to be involved in anchoring the cell membrane to the cell's 
cytoskele ton . 
N eurilemmomatosis is characterized by multiple cutaneous n e u_ 
rilemmomas and spinal schwannomas, without other signs of NFl 
or NF2. Many patients with neurilemmomatosis have multiple 
cutaneous ne urilemmomas associated with schw3l1l10mas of the 
spinal cord, paraspinal cord, c ran ial nerves, and viscera, and 
sometimes m eningiomas, gliomas, and astrocytomas . It is said that 
multiple cutaneous n e urile mmomas are a manifestation of a sys_ 
temic disease. External physical signs of neurilemmomatosis are 
often subtl e or absent or have bee n confi.lsed with NFL The 
Met Lys Trp Lys Gly Lys AsP 
A T G :!bAG T G G AA AG,lbG A AG G ACC 
LysArgGlu Gly 
codon42 
control 
case 1 
Figure 4. Nucleotide sequence of the NF2 gene in 1I0rmal DNA 
from ease 1. Direct sequencing of set-l region revealed a G i.nsertion at 
codon 42. 
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diagnosis is usually made by a denl1atologist when cutaneous 
neurilemmomas develop. 
In this study, using probes that span the NF2 gene, we fowld 
partial monosomy of chromosome 22 in three of seven cutaneous 
neurilemmomas (Fig 2). SSCP analysis of the NFl gene of 
neurilemmomatosis patients showed a nonnal pattenl of SSCP 
bands. We detected the germ-line mutations in two of three tumors 
from the same three patients. Mutations in the NF2 gene were 
deletion from codon 334 to 579 at least, and G insertion at codon 
42. This finding suggests that the neurilemmomatosis locus lies 
within the NF2 region and that these diseases might be identical. 
Patients with neurilemmomatosis eventually may develop acoustic 
neuromas, and tills neurilemmomatosis may be NF2 without 
acoustic neuromas. The patients with NF2 are prone to multiple 
neurilemmomas, including cutaneous and extracutaneous tunlors, 
whereas the patients with NFl may have multiple neurofibromas. 
Therefore, we would rather use the name neurilemmomatosis 
instead of NF2. 
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